Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Muraglitazar · 9 trials · 8 indications
| Name | Type | Description |
|---|---|---|
| Muraglitazar | DRUG | - |
| Pioglitazone | DRUG | - |
Inclusion Criteria: * Type 2 Diabetes * HbA1c \> = 8.0% and \< = 12.0% * Serum triglyceride concentration \< = 600 mg/dL * Fasting c-peptide \> = 1.0 ng/ml * Body mass index \< = 41 kg/m2 * Drug naive patients Exclusion Criteria: * History of MI (myocardial infarction), coronary angioplasty or by...
Muraglitazar is an investigational small molecule being developed for the treatment of Type 2 Diabetes Mellitus and related metabolic diabetes conditions. It was studied in Phase 3 clinical trials as a potential therapy for patients with Type 2 Diabetes, including in combination with other antidiabetic medications.
Muraglitazar is a dual peroxisome proliferator-activated receptor (PPAR) agonist, targeting both PPAR-alpha and PPAR-gamma. This mechanism is designed to improve glycemic control and lipid metabolism in patients with Type 2 Diabetes Mellitus.
Muraglitazar is being developed by Bristol-Myers Squibb Company, which trades under the ticker symbol BMY on the New York Stock Exchange. The company conducted Phase 3 clinical trials to evaluate the drug's safety and efficacy in treating Type 2 Diabetes.
Muraglitazar is in Phase 3 clinical development. It has completed multiple Phase 3 trials, but it remains an investigational drug and is not approved by regulatory authorities. The completed trials studied its use in Type 2 Diabetes Mellitus, both as monotherapy and in combination with other treatments.
Muraglitazar has completed four Phase 3 clinical trials. These include NCT00106808 comparing it to pioglitazone, NCT00162175 combining it with sulfonylurea, NCT00162240 combining it with metformin, and NCT00240370 evaluating metformin combined with muraglitazar or pioglitazone. All trials were completed with a total enrollment of 1,794 patients.
No, Muraglitazar is not the same as pioglitazone. Pioglitazone is a separate PPAR-gamma agonist used as an active comparator in clinical trials. Muraglitazar is a distinct dual PPAR-alpha and PPAR-gamma agonist developed by Bristol-Myers Squibb, and it was studied against pioglitazone in the Phase 3 trial NCT00106808.